4,561
Participants
Start Date
January 23, 2008
Primary Completion Date
October 15, 2008
Study Completion Date
March 19, 2009
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Two intramuscular injections at Days 0 and 21.
Placebo
Two intramuscular injections at Days 0 and 21.
GSK Investigational Site, Poughkeepsie
GSK Investigational Site, Rochester
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Erie
GSK Investigational Site, Rockville
GSK Investigational Site, Raleigh
GSK Investigational Site, Spartanburg
GSK Investigational Site, Stockbridge
GSK Investigational Site, Jacksonville
GSK Investigational Site, Melbourne
GSK Investigational Site, Pembroke Pines
GSK Investigational Site, Miami
GSK Investigational Site, Huntsville
GSK Investigational Site, Nashville
GSK Investigational Site, Cleveland
GSK Investigational Site, South Bend
GSK Investigational Site, Missoula
GSK Investigational Site, Chicago
GSK Investigational Site, Peoria
GSK Investigational Site, St Louis
GSK Investigational Site, Lenexa
GSK Investigational Site, Wichita
GSK Investigational Site, Metairie
GSK Investigational Site, Fort Worth
GSK Investigational Site, San Angelo
GSK Investigational Site, Austin
GSK Investigational Site, Phoenix
GSK Investigational Site, Las Vegas
GSK Investigational Site, Anaheim
GSK Investigational Site, Edison
GSK Investigational Site, Halifax
GSK Investigational Site, Truro
GSK Investigational Site, Greater Sudbury
GSK Investigational Site, London
GSK Investigational Site, Sarnia
GSK Investigational Site, Woodstock
GSK Investigational Site, Pointe-Claire
GSK Investigational Site, Québec
GSK Investigational Site, Saint Romuald
GSK Investigational Site, Sherbrooke
Lead Sponsor
GlaxoSmithKline
INDUSTRY